-
2022-502746-27-00
5
2020-08-21
Endometrial Cancer
-
2024-515379-36-00
9
2020-08-04
Metastatic pancreatic ductal adenocarcinoma
-
2024-515953-52-00
5
2020-07-24
Post-Essential Thrombocythaemia Myelofibrosis
-
2024-514434-20-00
5
2020-06-29
Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)
-
2022-502844-11-00
5
2020-01-29
severe to moderately severe hemophilia B (FIX:C ≤ 2%)
-
2023-508830-33-00
4
2019-12-13
Patients diagnosed with advanced or metastatic cancer treated with Tra
-
2024-517705-93-00
9
2019-12-13
Histologically or cytologically confirmed diagnosis of extensive or li
-
2023-508635-31-00
5
2019-12-03
Hepatocellular Carcinoma
-
2023-505980-36-00
5
2019-09-19
Primary progressive multiple sclerosis (PPMS)
-
2024-516847-23-00
4
2019-08-27
ER-positive and HER2-negative metastatic or locally advanced breast ca
-
2023-510268-11-00
4
2019-06-11
Cervical cancer
-
2023-510357-42-00
5
2019-05-22
hormone receptor (HR)-positive, HER2-negative,
early breast cancer (EB
-
2023-509087-20-00
5
2019-04-16
Metastatic Castration-resistant Prostate Cancer
-
2023-507906-15-00
5
2019-01-30
Relapsing multiple sclerosis (RMS)
-
2023-506125-10-00
5
2018-12-24
Multiple Myeloma
-
2024-511365-11-00
5
2018-11-27
Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
-
2024-516905-22-00
5
2018-10-22
Multiple myeloma
-
2024-510967-41-00
5
2018-09-21
Metastatic colorectal cancer
-
2023-504581-29-00
7
2018-04-26
Multiple myeloma
-
2024-513070-21-00
4
2018-02-15
Relapsed Acute Lymphoblastic Leukemia (ALL)
-
2024-514417-34-00
5
2017-12-14
Cancer
-
2024-512789-32-00
5
2017-10-09
Unresectable or metastatic soft tissue sarcoma
-
2024-515499-12-00
5
2017-10-02
Acute lymphoblastic leukemia
-
2023-506390-35-00
1
2017-04-19
Patients with Advanced Solid Tumors